文献速递垂体与肾上腺疾病骨质疏松与钙磷/甲状旁腺

醛固酮与血管紧张素II对PTH的调节在高醛固酮血症中减弱,肾上腺切除后可恢复

PTH Modulation by Aldosterone and Angiotensin II is Blunted in Hyperaldosteronism and Rescued by Adrenalectomy.
PubMed 文献 · J Clin Endocrinol Metab · 2019-01-01

研究探讨肾素-血管紧张素-醛固酮系统对甲状旁腺激素(PTH)的调节。口服卡托普利可降低原发性高血压和肾上腺切除后APA患者的PTH,但对未手术的原发性醛固酮增多症(APA和BAH)无效。体外实验显示醛固酮和血管紧张素II直接刺激人甲状旁腺细胞分泌PTH,分别通过盐皮质激素受体和AT1受体介导。

要点

  • 卡托普利可降低EH和肾上腺切除后APA患者的PTH水平。
  • 未手术的原发性醛固酮增多症患者对卡托普利的PTH降低作用不敏感。
  • 醛固酮和血管紧张素II通过MR和AT1受体直接刺激甲状旁腺细胞分泌PTH。

核心结论

  • 肾素-血管紧张素-醛固酮系统参与人体PTH调节,至少对甲状旁腺肿瘤来源的PTH分泌细胞如此。
  • 轻度甲状旁腺功能亢进是人类原发性醛固酮增多症的特征之一,且可通过肾上腺切除纠正。

研究设计与样本

  • 在原发性高血压(EH)和原发性醛固酮增多症(PA,包括双侧肾上腺增生BAH和醛固酮瘤APA)患者中,观察口服卡托普利(50 mg)引起的血清PTH变化,APA患者还在肾上腺切除前后分别评估。
  • 体外培养人甲状旁腺细胞(来自原发性甲状旁腺功能亢进患者),暴露于血管紧张素II(10-7 M)和/或醛固酮(10-7 M)。

主要发现

  • EH患者(n=63)卡托普利后PTH从25.9 ± 8.3 ng/L降至24.4 ± 8.0 ng/L(P < 0.0001)。
  • 肾上腺切除后APA患者(n=27)卡托普利后PTH从26.3 ± 11.6 ng/L降至24.0 ± 9.7 ng/L(P = 0.021)。
  • 卡托普利对未手术的APA和BAH所致完全型PA患者无效。
  • 体外实验中,醛固酮(P < 0.001)和血管紧张素II(P = 0.002)均显著增加甲状旁腺细胞PTH分泌,效应可分别被坎利酮和厄贝沙坦阻断。

临床怎么用

  • 对于原发性醛固酮增多症患者,应关注PTH水平,轻度甲状旁腺功能亢进可能是其表现之一。
  • 肾上腺切除可能纠正PA相关的PTH升高,但需进一步验证。

局限性

  • 体外实验使用的是甲状旁腺肿瘤来源的细胞,可能不能完全代表正常甲状旁腺。
  • 研究未报告正常甲状旁腺细胞或非肿瘤来源细胞的实验结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Accumulating evidence suggests a link between adrenocortical zona glomerulosa and parathyroid gland through mechanisms that remain unexplored. OBJECTIVES: To test the hypothesis that in vivo angiotensin II blockade affects PTH secretion in patients with hypertension and that aldosterone and angiotensim II directly stimulate PTH secretion ex vivo. DESIGN AND SETTING: We investigated the changes of serum PTH levels induced by oral captopril (50 mg) administration in patients with primary essential hypertension (EH) and with primary aldosteronism (PA) caused by bilateral adrenal hyperplasia (BAH) or aldosterone-producing adenoma (APA), the latter before and after adrenalectomy. We also exposed primary cultures of human parathyroid cells from patients with primary hyperparathyroidism to angiotensin II (10-7 M) and/or aldosterone (10-7 M). RESULTS: Captopril lowered PTH levels (in nanograms per liter) both in patients with EH (n = 63; 25.9 ± 8.3 baseline vs 24.4 ± 8.0 postcaptopril, P < 0.0001) and in patients with APA after adrenalectomy (n = 27; 26.3 ± 11.6 vs 24.0 ± 9.7 P = 0.021). However, it was ineffective in patients with full-blown PA caused by APA and BAH. In primary culture of human parathyroid cells, both aldosterone (P < 0.001) and angiotensin II (P = 0.002) markedly increased PTH secretion from baseline, by acting through mineralocorticoid receptor and angiotensin type 1 receptor, as these effects were abolished by canrenone and irbesartan, respectively. CONCLUSION: These results collectively suggest an implication of the renin-angiotensin-aldosterone system in PTH regulation in humans, at least in PTH-secreting cells obtained from parathyroid tumors. Moreover, they further support the concept that mild hyperparathyroidism is a feature of human PA that is correctable with adrenalectomy.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Lenzini L, Prisco S, Vanderriele PE, et al. PTH Modulation by Aldosterone and Angiotensin II is Blunted in Hyperaldosteronism and Rescued by Adrenalectomy. J Clin Endocrinol Metab. 2019. PMID: 30865228. doi:10.1210/jc.2019-00143

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。